Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

By afschroeder • August 13, 2025

Lambertini M, Allegranza D, Laubender RP, Harbeck N, Swain SM, Geyer CE, Slamon DJ, Bobba G, Lambertini C, de Haas S, Restuccia E, Vaz-Luis I, Cameron DA, Krop IE, Winer EP, Anderson RA. Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients. J Natl Cancer Inst. 2025 Aug 12:djaf198. doi: 10.1093/jnci/djaf198. Epub ahead of print. PMID: 40796347.

Tags: Hematology/Oncology, Publications

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits[...]

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq[...]

Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients

Moore TW, Spiliotopoulos E, Callahan RL, Kirschbaum CW, Bailey CF, Kim HJ, Roskams-Hieter B, Goncalves F, Keith D, Grossberg AJ, Spellman PT, Mills GB, Sears[...]